-
1
-
-
2942602706
-
Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11
-
Shigesada K, van de Sluis B, Liu PP: Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene 23:4297-4307, 2004
-
(2004)
Oncogene
, vol.23
, pp. 4297-4307
-
-
Shigesada, K.1
van de Sluis, B.2
Liu, P.P.3
-
2
-
-
2942516037
-
The 8;21 translocation in leukemogenesis
-
Peterson LF, Zhang DE: The 8;21 translocation in leukemogenesis. Oncogene 23:4255-4262, 2004
-
(2004)
Oncogene
, vol.23
, pp. 4255-4262
-
-
Peterson, L.F.1
Zhang, D.E.2
-
3
-
-
38949105508
-
Gatekeeper function of the RUNX1 transcription factor in acute leukemia
-
Niebuhr B, Fischer M, Tager M, et al: Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells Mol Dis 40:211-218, 2008
-
(2008)
Blood Cells Mol Dis
, vol.40
, pp. 211-218
-
-
Niebuhr, B.1
Fischer, M.2
Tager, M.3
-
4
-
-
0032793987
-
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
-
Byrd JC, Dodge RK, Carroll A, et al: Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767-3775, 1999
-
(1999)
J Clin Oncol
, vol.17
, pp. 3767-3775
-
-
Byrd, J.C.1
Dodge, R.K.2
Carroll, A.3
-
5
-
-
33748747555
-
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
-
Appelbaum FR, Kopecky KJ, Tallman MS, et al: The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135:165-173, 2006
-
(2006)
Br J Haematol
, vol.135
, pp. 165-173
-
-
Appelbaum, F.R.1
Kopecky, K.J.2
Tallman, M.S.3
-
6
-
-
17544388046
-
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
-
Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
-
(1998)
Cancer Res
, vol.58
, pp. 4173-4179
-
-
Bloomfield, C.D.1
Lawrence, D.2
Byrd, J.C.3
-
7
-
-
1842614240
-
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461
-
Byrd JC, Ruppert AS, Mrozek K, et al: Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol 22:1087-1094, 2004
-
(2004)
J Clin Oncol
, vol.22
, pp. 1087-1094
-
-
Byrd, J.C.1
Ruppert, A.S.2
Mrozek, K.3
-
8
-
-
0035469883
-
The predictive value of hierarchical cytogenetic classifi-cation in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
-
Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classifi-cation in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
-
(2001)
Blood
, vol.98
, pp. 1312-1320
-
-
Grimwade, D.1
Walker, H.2
Harrison, G.3
-
9
-
-
3042782698
-
The benefit of induction chemotherapy in patients age > or = 75 years
-
Vey N, Coso D, Bardou VJ, et al: The benefit of induction chemotherapy in patients age > or = 75 years. Cancer 101:325-331, 2004
-
(2004)
Cancer
, vol.101
, pp. 325-331
-
-
Vey, N.1
Coso, D.2
Bardou, V.J.3
-
10
-
-
4644234164
-
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups
-
Schoch C, Kern W, Schnittger S, et al: The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 89:1082-1090, 2004
-
(2004)
Haematologica
, vol.89
, pp. 1082-1090
-
-
Schoch, C.1
Kern, W.2
Schnittger, S.3
-
11
-
-
33745191374
-
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
-
Farag SS, Archer KJ, Mrozek K, et al: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108:63-73, 2006
-
(2006)
Blood
, vol.108
, pp. 63-73
-
-
Farag, S.S.1
Archer, K.J.2
Mrozek, K.3
-
12
-
-
24944464648
-
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study
-
Marcucci G, Mrozek K, Ruppert AS, et al: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 23:5705-5717, 2005
-
(2005)
J Clin Oncol
, vol.23
, pp. 5705-5717
-
-
Marcucci, G.1
Mrozek, K.2
Ruppert, A.S.3
-
13
-
-
0038156371
-
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup
-
Delaunay J, Vey N, Leblanc T, et al: Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood 102:462-469, 2003
-
(2003)
Blood
, vol.102
, pp. 462-469
-
-
Delaunay, J.1
Vey, N.2
Leblanc, T.3
-
14
-
-
0034010518
-
Measuring comorbidity in older cancer patients
-
Extermann M: Measuring comorbidity in older cancer patients. Eur J Cancer 36:453-471, 2000
-
(2000)
Eur J Cancer
, vol.36
, pp. 453-471
-
-
Extermann, M.1
-
15
-
-
33644521267
-
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome
-
Kantarjian H, O'Brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 106:1090-1098, 2006
-
(2006)
Cancer
, vol.106
, pp. 1090-1098
-
-
Kantarjian, H.1
O'Brien, S.2
Cortes, J.3
-
16
-
-
33947499161
-
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
-
Etienne A, Esterni B, Charbonnier A, et al: Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 109:1376-1383, 2007
-
(2007)
Cancer
, vol.109
, pp. 1376-1383
-
-
Etienne, A.1
Esterni, B.2
Charbonnier, A.3
-
17
-
-
0017162163
-
Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group
-
Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
-
(1976)
Br J Haematol
, vol.33
, pp. 451-458
-
-
Bennett, J.M.1
Catovsky, D.2
Daniel, M.T.3
-
18
-
-
36349005328
-
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: The BGMT 95 trial results
-
Pigneux A, Perreau V, Jourdan E, et al: Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: The BGMT 95 trial results. Haematologica 92:1327-1334, 2007
-
(2007)
Haematologica
, vol.92
, pp. 1327-1334
-
-
Pigneux, A.1
Perreau, V.2
Jourdan, E.3
-
19
-
-
0004313674
-
A placebocontrolled study of recombinant human granulocytemacrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM)
-
Witz F, Sadoun A, Perrin MC, et al: A placebocontrolled study of recombinant human granulocytemacrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 91:2722-2730, 1998
-
(1998)
Blood
, vol.91
, pp. 2722-2730
-
-
Witz, F.1
Sadoun, A.2
Perrin, M.C.3
-
20
-
-
3042667021
-
Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM data
-
suppl 1
-
Witz F, Harousseau JL, Guilhot F, et al: Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM data. Ann Hematol 83:S55-S57, 2004 (suppl 1)
-
(2004)
Ann Hematol
, vol.83
-
-
Witz, F.1
Harousseau, J.L.2
Guilhot, F.3
-
21
-
-
4944234928
-
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study
-
Castaigne S, Chevret S, Archimbaud E, et al: Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: Long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 104:2467-2474, 2004
-
(2004)
Blood
, vol.104
, pp. 2467-2474
-
-
Castaigne, S.1
Chevret, S.2
Archimbaud, E.3
-
22
-
-
34250157761
-
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
-
Gardin C, Turlure P, Fagot T, et al: Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109:5129-5135, 2007
-
(2007)
Blood
, vol.109
, pp. 5129-5135
-
-
Gardin, C.1
Turlure, P.2
Fagot, T.3
-
23
-
-
33750136033
-
Noninfusional versus intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: Final results of the EORTC-GIMEMA AML-13 randomized phase III trial
-
Jehn U, Suciu S, Thomas X, et al: Noninfusional versus intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: Final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia 20: 1723-1730, 2006
-
(2006)
Leukemia
, vol.20
, pp. 1723-1730
-
-
Jehn, U.1
Suciu, S.2
Thomas, X.3
-
24
-
-
1542753559
-
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
-
Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
-
(2003)
J Clin Oncol
, vol.21
, pp. 4642-4649
-
-
Cheson, B.D.1
Bennett, J.M.2
Kopecky, K.J.3
-
25
-
-
0037093053
-
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup
-
Nguyen S, Leblanc T, Fenaux P, et al: A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood 99:3517-3523, 2002
-
(2002)
Blood
, vol.99
, pp. 3517-3523
-
-
Nguyen, S.1
Leblanc, T.2
Fenaux, P.3
-
26
-
-
9344237642
-
Fiftyone patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor
-
Schoch C, Haase D, Haferlach T, et al: Fiftyone patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor. Leukemia 10:1288-1295, 1996
-
(1996)
Leukemia
, vol.10
, pp. 1288-1295
-
-
Schoch, C.1
Haase, D.2
Haferlach, T.3
-
27
-
-
4644288302
-
-
Schlenk RF, Benner A, Krauter J, et al: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741-3750, 2004
-
Schlenk RF, Benner A, Krauter J, et al: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741-3750, 2004
-
-
-
-
28
-
-
34249340637
-
Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia
-
Mrozek K, Bloomfield CD: Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 169-177, 2006
-
(2006)
Hematology Am Soc Hematol Educ Program
, vol.169-177
-
-
Mrozek, K.1
Bloomfield, C.D.2
-
29
-
-
33744487375
-
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
-
Boissel N, Leroy H, Brethon B, et al: Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965-970, 2006
-
(2006)
Leukemia
, vol.20
, pp. 965-970
-
-
Boissel, N.1
Leroy, H.2
Brethon, B.3
-
30
-
-
33748467435
-
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): A Cancer and Leukemia Group B Study
-
Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8; 21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006
-
(2006)
J Clin Oncol
, vol.24
, pp. 3904-3911
-
-
Paschka, P.1
Marcucci, G.2
Ruppert, A.S.3
-
31
-
-
33846433493
-
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
-
Giles FJ, Borthakur G, Ravandi F, et al: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624-627, 2007
-
(2007)
Br J Haematol
, vol.136
, pp. 624-627
-
-
Giles, F.J.1
Borthakur, G.2
Ravandi, F.3
-
32
-
-
57549098626
-
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
-
Malfuson JV, Etienne A, Turlure P, et al: Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 93:1806-1813, 2008
-
(2008)
Haematologica
, vol.93
, pp. 1806-1813
-
-
Malfuson, J.V.1
Etienne, A.2
Turlure, P.3
-
33
-
-
0032751381
-
Management of acute myeloid leukemia in elderly patients
-
Hiddemann W, Kern W, Schoch C, et al: Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17:3569-3576, 1999
-
(1999)
J Clin Oncol
, vol.17
, pp. 3569-3576
-
-
Hiddemann, W.1
Kern, W.2
Schoch, C.3
-
34
-
-
23844507573
-
Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
-
Rowe JM: Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)? Leukemia 19:1324-1327, 2005
-
(2005)
Leukemia
, vol.19
, pp. 1324-1327
-
-
Rowe, J.M.1
-
35
-
-
51649089123
-
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
-
Candoni A, Martinelli G, Toffoletti E, et al: Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 32:1800-1808, 2008
-
(2008)
Leuk Res
, vol.32
, pp. 1800-1808
-
-
Candoni, A.1
Martinelli, G.2
Toffoletti, E.3
-
36
-
-
58149220896
-
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival
-
Borthakur G, Kantarjian H, Wang X, et al: Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 113:3181-3185, 2008
-
(2008)
Cancer
, vol.113
, pp. 3181-3185
-
-
Borthakur, G.1
Kantarjian, H.2
Wang, X.3
-
37
-
-
33745586575
-
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
-
Faderl S, Verstovsek S, Cortes J, et al: Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45-51, 2006
-
(2006)
Blood
, vol.108
, pp. 45-51
-
-
Faderl, S.1
Verstovsek, S.2
Cortes, J.3
-
38
-
-
38349185874
-
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: Collaborative study between the German AML Intergroup and CIBMTR
-
Schlenk RF, Pasquini MC, Perez WS, et al: HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: Collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant 14:187-196, 2008
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, pp. 187-196
-
-
Schlenk, R.F.1
Pasquini, M.C.2
Perez, W.S.3
-
39
-
-
27244434510
-
Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment
-
Blaise DP, Michel Boiron J, Faucher C, et al: Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 104:1931-1938, 2005
-
(2005)
Cancer
, vol.104
, pp. 1931-1938
-
-
Blaise, D.P.1
Michel Boiron, J.2
Faucher, C.3
-
40
-
-
38949163678
-
FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia
-
Kim HG, Kojima K, Swindle CS, et al: FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. Blood 111:1567-1574, 2008
-
(2008)
Blood
, vol.111
, pp. 1567-1574
-
-
Kim, H.G.1
Kojima, K.2
Swindle, C.S.3
-
41
-
-
55749083387
-
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
-
Mrózek K, Marcucci G, Paschka P, et al: Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 20:711-718, 2008
-
(2008)
Curr Opin Oncol
, vol.20
, pp. 711-718
-
-
Mrózek, K.1
Marcucci, G.2
Paschka, P.3
|